/PRNewswire/ Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4.
AUO Partners with Acer to Introduce Pioneering AmLED Technology in Predator Helios 500 Gaming Notebooks
Share Article
Embracing both technology innovation and sustainability commitment to bring about the realization of “AUO NEXT” transformation strategy
AUO has led to launch the proprietary AmLED (Adaptive mini LED) display technology to achieve revolutionary performance in gaming displays.
AmLED (Adaptive mini LED) display technology enhances mini LED backlight design. HSINCHU, Taiwan (PRWEB) June 02, 2021 AUO has long dedicated itself to the development of advanced display technologies, and pioneered to develop the mini LED technology years ago. Today AUO proudly presents the introduction of its all-new AmLED (Adaptive mini LED) display technology for Acer’s newly launched Predator Helios 500 Gaming Notebook, featuring the world’s highest performance gaming notebook PC display( ) with 4K resolution, 1
Fury Provides Regional Update at Eau Claire and Targets High-Grade Plunge at Percival
ACCESSWIRE
TORONTO, ON / ACCESSWIRE / June 2, 2021 /
Fury Gold Mines Limited (TSX:FURY) and (NYSE American:FURY) ( Fury or the Company ) is pleased to announce an updated geological framework that has enhanced the regional targeting at the Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec. Targets have been refined through the re-interpretation of airborne magnetic and electro-magnetic surveys and associated 3D inversions (Figure 1). Target areas are defined by complex structural zones and associated favourable lithologies that highlight two distinct styles of mineralization: quartz-tourmaline vein systems, as observed at the Eau Claire deposit, and sedimentary hosted breccias that characterize the Percival prospect, located approximately 14 kilometres east of Eau Claire along the Cannard Deformation Zone (Figure 2).
Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology Early data from ongoing PROTECT trial suggest stable and durable response to KRYSTEXXA (pegloticase injection) therapy in treating uncontrolled gout among people with kidney transplants Data on the company s investigational compound (HZN-4920) under evaluation for rheumatoid arthritis will be presented during an oral session on June 3 at 10:15 a.m. CEST
Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a kidney transplant.
/PRNewswire/ Zepp Health Corp. (NYSE: ZEPP), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced that.